Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update

被引：497

作者：

Kaufmann, M

Hortobagyi, GN

Goldhirsch, A

Scholl, S

Makris, A

Valagussa, P

Blohmer, JU

Eiermann, W

Jackesz, R

Jonat, W

Lebeau, A

Loibl, S

Miller, W

Seeber, S

Semiglazov, V

Smith, R

Souchon, R

Stearns, V

Untch, M

von Minckwitz, G

机构：

[1] Goethe Univ Frankfurt, D-6000 Frankfurt, Germany

[2] St Gertrauden, Berlin, Germany

[3] Krankenhaus Roten Kreuz, Frauenklin, Munich, Germany

[4] Univ Munich, Inst Pathol, D-8000 Munich, Germany

[5] Univ Hosp, Kiel, Germany

[6] Tumorzentrum, Essen, Germany

[7] Allgemeines Krankenhaus Hagen, Hagen, Germany

[8] German Breast Grp, Neu Isenburg Frankfurt, Germany

[9] European Sch Oncol, Milan, Italy

[10] Ist Nazl Tumori, I-20133 Milan, Italy

[11] Inst Curie, Paris, France

[12] Mt Vernon Hosp, Northwood HA6 2RN, Middx, England

[13] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland

[14] Univ Edinburgh, Edinburgh, Midlothian, Scotland

[15] Univ Klin Chirurg, Vienna, Austria

[16] NN Petrov Oncol Res Inst, St Petersburg, Russia

[17] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[18] Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA

[19] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 12期

关键词：

D O I：

10.1200/JCO.2005.02.6187

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.

引用

页码：1940 / 1949

页数：10

共 62 条

[1] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].

Ayers, M ;

Symmans, WF ;

Stec, J ;

Damokosh, AI ;

Clark, E ;

Hess, K ;

Lecocke, M ;

Metivier, J ;

Booser, D ;

Ibrahim, N ;

Valero, V ;

Royce, M ;

Arun, B ;

Whitman, G ;

Ross, J ;

Sneige, N ;

Hortobagyi, GN ;

Pusztai, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293

[2] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Brown, A ;

Smith, R ;

Mamounas, EP ;

Fisher, B ;

Margolese, R ;

Theoret, H ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174

[3]

Bear HD, 2004, BREAST CANCER RES TR, V88, pS16

[4]

Bines J, 2003, BREAST CANCER RES TR, V82, pS56

[5] Neoadjuvant chemotherapy in young breast cancer patients:: Correlation between response and relapse? [J].

Braud, AC ;

Asselain, B ;

Scholl, S ;

De la Rochefordière, A ;

Palangie, T ;

Dieras, V ;

Pierga, JY ;

Dorval, T ;

Jouve, M ;

Beuzeboc, P ;

Pouillart, P .

EUROPEAN JOURNAL OF CANCER, 1999, 35 (03) :392-397

[6] Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study [J].

Burstein, HJ ;

Harris, LN ;

Gelman, R ;

Lester, SC ;

Nunes, RA ;

Kaelin, CM ;

Parker, LM ;

Ellisen, LW ;

Kuter, I ;

Gadd, MA ;

Christian, RL ;

Kennedy, PR ;

Borges, VF ;

Bunnell, CA ;

Younger, J ;

Smith, BL ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :46-53

[7] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].

Buzdar, AU ;

Ibrahim, NK ;

Francis, D ;

Booser, DJ ;

Thomas, ES ;

Theriault, RL ;

Pusztai, L ;

Green, MC ;

Arun, BK ;

Giordano, SH ;

Cristofanilli, M ;

Frye, DK ;

Smith, TL ;

Hunt, KK ;

Singletary, SE ;

Sahin, AA ;

Ewer, MS ;

Buchholz, TA ;

Berry, D ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685

[8] Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer [J].

Buzdar, AU ;

Singletary, SE ;

Theriault, RL ;

Booser, DJ ;

Valero, V ;

Ibrahim, N ;

Smith, TL ;

Asmar, L ;

Frye, D ;

Manuel, N ;

Kau, SW ;

McNeese, M ;

Strom, E ;

Hunt, K ;

Ames, F ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3412-3417

[9] Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy [J].

Cameron, DA ;

Anderson, EDC ;

Levack, P ;

Hawkins, RA ;

Anderson, TJ ;

Leonard, RCF ;

Forrest, APM ;

Chetty, U .

BRITISH JOURNAL OF CANCER, 1997, 76 (08) :1099-1105

[10] Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson Cancer Center experience [J].

Chen, AM ;

Meric-Bernstam, F ;

Hunt, KK ;

Thames, HD ;

Oswald, MJ ;

Outlaw, ED ;

Strom, EA ;

McNeese, MD ;

Kuerer, HM ;

Ross, MI ;

Singletary, SE ;

Ames, FC ;

Feig, BW ;

Sahin, AA ;

Perkins, GH ;

Schechter, NR ;

Hortobagyi, GN ;

Buchholz, TA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2303-2312

← 1 2 3 4 5 6 7 →